# Kheiron Medical Technologies

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/kheiron-medical-technologies

- Industry: Software
- Headquarters: London, UK
- Website: www.kheironmed.com
- Total disclosed funding: $25M
- Latest round: Series A (Jun 12, 2019)
- Investors on record: 7

## About

Kheiron Medical Technologies specializes in AI-driven solutions for breast cancer screening, enabling improved diagnostic accuracy and decision-making support for healthcare providers.Founded in 2016 in London, UK, Kheiron Medical Technologies develops innovative AI technologies aimed at enhancing breast cancer screening. The company has undergone strategic development, leading to its acquisition by DeepHealth in October 2024, which aims to expand AI-powered diagnostic solutions in Europe. The co-founders, Peter Kecskemethy and Tobias Rijken, have a background in healthcare technology, and Peter Kecskemethy serves as the CEO. Kheiron has successfully completed 8 funding deals with its most recent funding round, Series A, raising GBP 19.4 mn led by Atomico, bringing the total amount raised to GBP 19.4 mn and the current company valuation to GBP 61.198 mn.Kheiron Medical Technologies primarily offers its flagship product, Mia, an AI platform designed to aid in breast cancer screening. Mia analyzes mammographic images to assist radiologists in determining whether a patient requires further testing, significantly improving cancer detection rates by 13% compared to traditional methods. Their services target healthcare providers, primarily in the UK and the US, with plans to expand internationally as demand for their technology increases.In 2023, Kheiron Medical Technologies reported a revenue of GBP 77,792 and an EBITDA loss of GBP 6,782,237.9. The company generates revenue through partnerships and subscription models with healthcare providers, allowing them to integrate Mia into screening processes, fostering long-term relationships as clients include structured agreements for access to their AI technology, along with training and support services.The acquisition by DeepHealth enables Kheiron Medical Technologies to expand its portfolio of AI diagnostic solutions. The acquisition, finalized on October 22, 2024, aims to accelerate the introduction of breast cancer solutions across Europe. Future growth strategies include launching new AI products and targeting expansions into specific markets, further enhancing Kheiron's reach and impact.

## Funding rounds

- Series A, Jun 12, 2019, $24M — Greycroft, Atomico, Connect Ventures, Hoxton Ventures, Exor Seeds
- Series A, Apr 3, 2017 — Greycroft
- Seed, Jun 15, 2016, $0M — Connect Ventures, Entrepreneur First, Isomer Capital

## Investors

- Connect Ventures — Seed, Series A
- Entrepreneur First (https://capitalatlas.ai/funds/entrepreneur-first) — Seed
- Isomer Capital (https://capitalatlas.ai/funds/isomer-capital) — Seed
- Greycroft (https://capitalatlas.ai/funds/greycroft) — Series A
- Atomico (https://capitalatlas.ai/funds/atomico) — Series A
- Hoxton Ventures (https://capitalatlas.ai/funds/hoxton-ventures) — Series A
- Exor Seeds — Series A